CN110713983B - 一种表达透明质酸酶的免疫细胞及其应用 - Google Patents
一种表达透明质酸酶的免疫细胞及其应用 Download PDFInfo
- Publication number
- CN110713983B CN110713983B CN201911067805.7A CN201911067805A CN110713983B CN 110713983 B CN110713983 B CN 110713983B CN 201911067805 A CN201911067805 A CN 201911067805A CN 110713983 B CN110713983 B CN 110713983B
- Authority
- CN
- China
- Prior art keywords
- leu
- val
- ser
- pro
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911067805.7A CN110713983B (zh) | 2019-11-04 | 2019-11-04 | 一种表达透明质酸酶的免疫细胞及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911067805.7A CN110713983B (zh) | 2019-11-04 | 2019-11-04 | 一种表达透明质酸酶的免疫细胞及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110713983A CN110713983A (zh) | 2020-01-21 |
CN110713983B true CN110713983B (zh) | 2022-06-10 |
Family
ID=69213742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911067805.7A Active CN110713983B (zh) | 2019-11-04 | 2019-11-04 | 一种表达透明质酸酶的免疫细胞及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110713983B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112226462A (zh) * | 2020-10-12 | 2021-01-15 | 广东昭泰体内生物医药科技有限公司 | 共表达分泌型il-7和选择性ccl19的表达载体及其应用 |
CN112210540A (zh) * | 2020-10-12 | 2021-01-12 | 广东昭泰体内生物医药科技有限公司 | 一种表达免疫调控因子的car-t细胞及其应用 |
CN114350691B (zh) * | 2021-03-05 | 2023-12-08 | 华熙生物科技股份有限公司 | 一种高效表达透明质酸水解酶的基因及其表达方法 |
CN114075569A (zh) * | 2021-11-17 | 2022-02-22 | 安徽中盛溯源生物科技有限公司 | 一种表达重组神经营养因子融合蛋白的方法、重组神经营养因子融合蛋白及其应用 |
CN114573715A (zh) * | 2022-03-14 | 2022-06-03 | 江苏雅酶医药科技有限公司 | 一种重组长效人透明质酸酶及其生产方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102805896A (zh) * | 2011-05-30 | 2012-12-05 | 惠觅宙 | 经皮给药方法、制剂和系统 |
KR20140043438A (ko) * | 2011-06-17 | 2014-04-09 | 할로자임, 아이엔씨 | 히알루로난 분해 효소의 안정한 제형 |
CN107400664A (zh) * | 2016-05-20 | 2017-11-28 | 蔡胜和 | 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用 |
TWI783957B (zh) * | 2016-12-23 | 2022-11-21 | 美商伊繆諾金公司 | 靶向adam9之免疫共軛物及其使用方法 |
EP3765516A2 (en) * | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
CN109536476A (zh) * | 2018-05-21 | 2019-03-29 | 沣潮医药科技(上海)有限公司 | 具备透明质酸酶活性的靶向融合蛋白、制备方法及用途 |
-
2019
- 2019-11-04 CN CN201911067805.7A patent/CN110713983B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110713983A (zh) | 2020-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110713983B (zh) | 一种表达透明质酸酶的免疫细胞及其应用 | |
CN110437339B (zh) | 一种以白介素15为活性成分的融合蛋白型药物前体 | |
RU2265661C2 (ru) | Слитый полипептид, способный связываться с полипептидом vegf, и кодирующая его молекула нуклеиновой кислоты, их получение и применение | |
CN102027123B (zh) | 使用人细胞表达系统重组产生可靠的人蛋白质 | |
CN108093638A (zh) | 经修饰的白细胞介素-7蛋白及其用途 | |
JP7423607B2 (ja) | インターロイキン 2突然変異タンパク質およびi型インターフェロンで構成される融合タンパク質 | |
EA004793B1 (ru) | Химерный белок растворимого рецептора интерлейкина-6/лиганда, его аналоги и способы применения | |
CN112724259B (zh) | 人血清白蛋白与白介素2的融合蛋白及其用途 | |
KR101985271B1 (ko) | Trail 및 cd를 발현하는 중간엽줄기세포 및 이의 용도 | |
CN114591445B (zh) | 新型人血清白蛋白突变体 | |
CN111892661B (zh) | 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用 | |
JP2021511060A (ja) | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 | |
CN108300699A (zh) | 修饰的nk细胞及其用途 | |
CN115838439B (zh) | 嵌合转换受体基因修饰的nk细胞制备方法及应用 | |
CN111819203A (zh) | 包含抗muc1抗体和il-15的融合蛋白构建体 | |
CN117343907A (zh) | 一种自分泌il7和il21的靶向cdh17的car-t细胞及其应用 | |
CN116041542A (zh) | 逆转肿瘤微环境抑制性信号的nk细胞制备方法及应用 | |
CN109666074B (zh) | 一种趋化因子受体cxcr5的用途 | |
CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
CN101037475B (zh) | 一种嵌合受体及其制备方法和用途 | |
CN111378046B (zh) | 一种免疫效应细胞转换受体 | |
WO2017201635A1 (zh) | 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用 | |
CN116239692A (zh) | 分离的抗体、包含该抗体的car及其用途 | |
US20240287152A1 (en) | Long-acting recombinant human interleukin-2 fusion protein, and preparation method therefor and application thereof | |
CN101257925A (zh) | 人干扰素α类似物和干扰素τ的低毒长循环的嵌合体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Peng Inventor after: Zhao Ruocong Inventor after: Tang Chaoyang Inventor after: Cui Yuanbin Inventor after: Lin Simiao Inventor after: Yao Yao Inventor before: Li Peng Inventor before: Zhao Ruocong Inventor before: Cui Yuanbin Inventor before: Lin Simiao Inventor before: Yao Yao Inventor before: Tang Chaoyang |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |